



Gerd-Rüdiger Burmester

Contact

Gerd-Rüdiger Burmester

Publications (3)

Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes I, Sattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, Ravelli A, Betteridge N, Burmester G, Bijlsma J, Bykerk V, Caporali R, Choy E, Codreanu C, Combe B, Crow M, de Wit M, Emery P, Fleischmann R, Gabay C, Hetland M, Hyrich K, Iagnocco A, Isaacs J, Kremer J, Mariette X, Merkel P, Mysler E, Nash P, Nurmohamed M, Pavelka K, Poór G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, Smolen J. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. *Ann Rheum Dis* 2022

Burmester G, Taylor P, Szekanecz Z, Stamm T, Rubbert-Roth A, Ramiro S, Østergaard M, Montecucco C, Iagnocco A, Gabay C, Ferreira R, Fautrel B, Durez P, Combe B, Calvo Alén J, Betteridge N, Álvaro-Gracia J, van de Laar M. Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. *Clin Exp Rheumatol* 2020; 38:1056-1067.

Dörner T, Peters M, Schwenke H, Rubbert-Roth A, Krüger K, Kurthen R, Kellner H, Kästner P, Engel A, Schmalzing M, Iking-Konert C, Burmester G, Schulze-Koops H, Tony H. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRA). *Clin Exp Rheumatol* 2019; 37:937-945.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch